Document:

<Page>

                                                                  EXHIBIT 10.25

                                Variagenics, Inc.
                                60 Hampshire St.
                               Cambridge, MA 02139

                          EXECUTIVE RETENTION AGREEMENT

CONFIDENTIAL

November 15, 2001

Taylor Jackson Crouch
83 Belcher Drive
Sudbury, MA 01776

Dear Taylor:

         This letter agreement (the "Retention Agreement") shall confirm our
agreement with respect to additional compensation you will receive in
connection with your continued service as the President and Chief Executive
Officer of Variagenics, Inc. (the "Company") during the [_____________]
period which commenced on October 11, 2001 and terminates on [______] (the
"Retention Period"). To the extent the Retention Agreement augments or
differs from the terms of your Employment Agreement dated March 18, 1999 (the
"Employment Agreement") or any of your Stock Option Agreements dated
September 22, 1999, February 11, 2000 or January 3, 2001 (collectively, the
"Option Agreements"), the Employment Agreement and the Option Agreements are
hereby amended to such extent.

         In addition to the existing terms and conditions of your Employment
Agreement and Option Agreements, this Retention Agreement confirms that if
you resign your employment at any time during the Retention Period, so long
as you provide a minimum of two (2) weeks advance notice in writing, such
resignation shall be treated as a resignation for Good Reason, pursuant to
the Employment Agreement, and any cash payments due pursuant to Section
4(b)(i) of the Employment Agreement shall be paid in a lump sum upon the
termination of your employment with the Company. In addition, because of the
crucial role you have agreed to take on with respect to certain critical
objectives during the Retention Period, you shall receive the compensation
and benefits noted below, subject to the following conditions:

CASH BONUSES

         Apart from continuing to be paid at the rate of $13,541.67 per
semi-monthly pay period as long as you remain employed by the Company, you
will be eligible to receive a total cash bonus of up $162,500 (the "Bonus
Potential") if you attain the following objectives during the Retention
Period:

         (a) RECRUITMENT--If a new Chief Science Officer/Vice President,
         Research & Development is hired during the Retention Period, you shall
         receive a payment equal to twenty-five percent (25%) of the total Bonus
         Potential within thirty (30) days following

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

<Page>

         the earlier of (i) the individual's first day of employment or (ii)
         the execution of an employment agreement between the Company and the
         individual;

         (b) STRATEGIC RELATIONSHIPS--If a letter of intent is executed with
         respect to a collaborative transaction with a pharmaceutical or biotech
         company [____________________________________________________________],
         you shall receive a payment equal to twelve and one-half percent
         (12.5%) of the total Bonus Potential within thirty (30) days following
         execution of such letter of intent. If a second such letter of intent
         is executed, you shall receive an additional payment equal to twelve
         and one-half percent (12.5%) of the total Bonus Potential within
         thirty (30) days following execution of such letter of intent;

         (c) [____________________________]--[_______________________________],
         you shall receive a payment equal to, you shall recieve a payment equal
         to twenty-five percent (25%) of the total Bonus Potential within thirty
         (30) days following execution of such letter of intent, provided,
         however, that [_______________________________________] during the
         Retention Period, this portion of the Bonus Potential shall be
         reallocated among the four (4) other cash bonus objectives on a pro
         rata basis; and

         (d) BUDGET--If you present to the Board of Directors a reasonably
         detailed written budget that demonstrably will [_____________________
         _____________] and confer with the Board of Directors regarding the
         same in the context of a Board Meeting, you shall receive a payment
         equal to twenty-five percent (25%) of the total Bonus Potential within
         thirty (30) days following such Board Meeting.

         Any cash payments shall be subject to customary federal, state and
local withholdings, and any Bonus Potential amounts actually earned during
the Retention Period that remain unpaid upon the expiration of the Retention
Period shall remain due and payable in accordance with the terms of preceding
paragraphs (a) - (d) in this Cash Bonuses section.

STOCK OPTIONS

         (a) EXISTING STOCK OPTIONS--Any stock options that were granted
         pursuant to the Option Agreements that have not vested as of the date
         of such resignation or termination shall vest and become exercisable
         upon the earlier of (i) [________________] or (ii) the date on which
         you resign your employment or the Company terminates your employment.
         To the extent permitted by law, such options shall remain exercisable
         for a period of one hundred eighty (180) days commencing on your final
         date of employment with the Company (so long as such exercise period
         does not exceed the expiration date of the particular options, as
         stated in the stock option agreement subject to which particular
         options were granted).

         (b) RETENTION STOCK OPTIONS--The Board of Directors, or their
         duly-authorized designees, shall grant you 175,500 stock options with
         an exercise price of $2.26 per share, subject to the terms of the
         Amended 1997 Employee, Director and Consultant

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       2
<Page>

         Stock Option Plan and a stock option agreement on the form most
         recently approved by the Board of Directors, as qualified by this
         paragraph (the "Retention Options"). If you are still employed by the
         Company on March 31, 2002 or your employment has been terminated at the
         directive of the Board of Directors prior thereto, 87,750 of such
         stock options shall vest and become exercisable as of that date. The
         remaining 87,500 shall vest and become exercisable as follows,
         assuming you remain employed by the Company on each vesting date:
         (i) 21,938 on April 30, 2002; (ii) 21,938 on May 31, 2002; (iii) 21,937
         on June 30, 2002; and (iv) 21,937 on July 10, 2002. To the extent
         permitted by law, any such stock options shall remain exercisable for
         a period of one hundred eighty (180) days commencing on your final date
         of employment with the Company (so long as such exercise period does
         not exceed the expiration date of such options, as stated in the stock
         option agreement subject to which such options may be granted).

         (c) PERFORMANCE STOCK OPTIONS--If, at a time when you are still
         employed by the Company during the Retention Period, the Company (i)
         [________________________] or (ii) [______________________________] or
         [________________________], the Board of Directors, or their
         duly-authorized designees, shall grant you 115,500 stock options with
         an exercise price of $2.26 per share, subject to the terms of the
         Amended 1997 Employee, Director and Consultant Stock Option Plan and a
         stock option agreement on the form most recently approved by the Board
         of Directors, as qualified by this paragraph. All such performance
         stock options shall vest and become exercisable upon the grant date. To
         the extent permitted by law, any such stock options shall remain
         exercisable for a period of one hundred eighty (180) days commencing on
         your final date of employment with the Company (so long as such
         exercise period does not exceed the expiration date of such options,
         as stated in the stock option agreement subject to which such options
         may be granted).

                  For the purpose of determining the period for which the any of
         the aforementioned options may be exercised, the expiration date of
         such options shall be deemed to be the expiration date set forth in the
         relevant agreement governing such options but disregarding the
         provisions for early termination of the options for any reason other
         than termination for "cause" as defined in such option agreement. In
         addition, the one hundred eighty (180) day period commencing on your
         final date of employment with the Company shall supersede any provision
         in the relevant agreement governing such options setting forth an
         exercise period for the options of less than one hundred eighty (180)
         days after your final date of employment with the Company.

                  Pursuant to the terms of the Amended 1997 Employee, Director
         and Consultant Stock Option Plan, you will be permitted to exercise
         the options noted above by using a cashless exercise program.

                  All shares of the Company's stock owned by you shall be
         subject to any restrictions imposed by law, and, [__________________
         ___________________________________________________________].

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       3
<Page>

NON-COMPETITION

         You hereby agree that the companies set forth on SCHEDULE A to this
Amended and Restated Retention Agreement, together with their respective
affiliates, successors and related entities, shall be the only entities to be
considered a Competing Business for purposes of Section 5 of the Employment
Agreement.

EXPENSES

         The Company shall reimburse you for up to $5,000 in legal fees
relating to the negotiation of this Retention Agreement, within thirty (30)
days following presentation of appropriate invoices to Martin Vogelbaum.

RELEASE AND WAIVER OF CLAIMS

         Your receipt of any cash, stock options or expense reimbursements
pursuant to the terms of the Retention Agreement is conditioned on your
execution of a full and complete release and waiver of claims with respect to
the Company, its directors, officers and shareholders (and its and their
successors and assigns) in a form satisfactory to (and provided by) the
Company upon the earlier of (i) [________________] or (ii) the date of the
termination of your employment with the Company for any reason. A current
example of a full and complete release is attached hereto as Exhibit A for
your review. Failure to execute and return such release and waiver of claims
to the Company within twenty-one (21) days of receipt, shall subject any
stock options granted hereunder to forfeiture and shall require you to repay
any cash payments provided hereunder upon the expiration of such twenty-one
(21) day period.

DISPUTE RESOLUTION

         To the extent that any disputes regarding this Retention Agreement
may arise, they shall be resolved in accordance with the terms of Section 10
of the Employment Agreement.

         We hope that you appreciate the unique nature of this arrangement
and we are pleased to recognize the important role we anticipate you will
play during the Retention Period. In order to accept this offer, you must
execute this letter where provided below and return it to Martin Vogelbaum,
by no later than November 15, 2001.

                                       VARIAGENICS, INC.

                                       By:  /s/ Martin A. Vogelbaum
                                          --------------------------------
                                          Martin A. Vogelbaum
                                          Director

ACCEPTED AND AGREED:

By:   /s/ Taylor J. Crouch
      --------------------
Date: 11/15/01
     --------------------

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       4
<Page>

                                     RELEASE

         You hereby agree and acknowledge that by signing this Release, you
are waiving your right to assert any form of legal claim against Variagenics,
Inc. ("Variagenics" or the "Company")(1) whatsoever for any alleged action,
inaction or circumstance existing or arising from the beginning of time
through the date on which you sign this Release. Your waiver and release
herein is intended to bar any form of legal claim, charge, complaint or any
other form of action (jointly referred to as "Claims") against Variagenics
seeking any form of relief including, without limitation, equitable relief
(whether declaratory, injunctive or otherwise), the recovery of any damages
or any other form of monetary recovery whatsoever (including, without
limitation, back pay, front pay, compensatory damages, emotional distress
damages, punitive damages, attorneys fees and any other costs) against
Variagenics for any alleged action, inaction or circumstance existing or
arising through the date on which you sign this Release.

         Without limiting the foregoing general waiver and release, you
specifically waive and release Variagenics from any Claims arising from or
related to your employment relationship with the Company or the termination
thereof, including without limitation:

         (i)      Claims under any local, state, federal or foreign
                  discrimination, fair employment practices or other employment
                  related statute, regulation or executive order (as they may
                  have been amended through the date on which you sign this
                  Release) prohibiting discrimination or harassment based upon
                  any protected status including, without limitation, race,
                  religion, citizenship, national origin, age, gender, genetic
                  carrier status, marital status, disability, veteran status or
                  sexual orientation. Without limitation, specifically included
                  in this paragraph are any Claims arising under the federal Age
                  Discrimination in Employment Act, the Older Workers Benefit
                  Protection Act, the Civil Rights Acts of 1866 and 1871, Title
                  VII of the Civil Rights Act of 1964, the Civil Rights Act of
                  1991, the Equal Pay Act, the Immigration Reform and Control
                  Act, the Americans With Disabilities Act and any similar
                  local, state, federal or foreign statute or law.

         (ii)     Claims under any other local, state, federal or foreign
                  employment related statute, regulation or executive order (as
                  they may have been amended through the date on which you sign
                  this Release) relating to wages, hours or any other terms and

-------------------------------

(1)     For the purposes of this Section the parties agree that the phrase,
"Variagenics, Inc.," shall include Variagenics, Inc., its divisions,
affiliates, parents and subsidiaries, and its and their respective officers,
directors, employees, agents and assigns.

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       5
<Page>

                  conditions of employment. Without limitation, specifically
                  included in this paragraph are any Claims arising under the
                  Fair Labor Standards Act, the Family and Medical Leave Act of
                  1993, the National Labor Relations Act, the Employee
                  Retirement Income Security Act of 1974, the Consolidated
                  Omnibus Budget Reconciliation Act of 1985 ("COBRA") and any
                  similar local, state, federal or foreign statute or law.

         (iii)    Claims under any local, state, federal or foreign common law
                  theory including, without limitation, wrongful discharge,
                  breach of express or implied contract, promissory estoppel,
                  unjust enrichment, breach of a covenant of good faith and fair
                  dealing, violation of public policy, defamation, interference
                  with contractual relations, intentional or negligent
                  infliction of emotional distress, invasion of privacy,
                  misrepresentation, deceit, fraud or negligence.

         (iv)     Claims under any local, state or federal securities law,
                  including, without limitation, the Securities Act of 1933, as
                  amended, the Securities Exchange Act of 1934, as amended, and
                  any Massachusetts, Delaware or other state or local securities
                  statutes and regulations.

         (v)      Any other Claim arising under local, state or federal law.

         You acknowledge and agree that but for providing this waiver and
release, you would not be receiving the consideration provided to you by the
Company through the Retention Agreement between you and the Company.

         Because you are more than forty (40) years of age, you have specific
rights under the Older Workers Benefits Protection Act ("OWBPA"), which
prohibits discrimination on the basis of age, and that the releases set forth
herein are intended to release any right that you may have to file a claim
against the Company alleging discrimination on the basis of age.

         It is the Company's desire and intent to make certain that you fully
understand the provisions and effects of this letter. To that end, you have
been encouraged and given the opportunity to consult with legal counsel for
the purpose of reviewing the terms of this Release. Consistent with the
provisions of OWBPA, your signature below confirms that the Company has
provided you with at least twenty-one (21) days in which to consider and
accept the terms of this

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       6
<Page>

Release. In addition, you may rescind your assent to this Agreement if,
within seven (7) days after you sign this Agreement, you deliver a written
notice of rescission to the Company's Board of Directors. To be effective,
such rescission must be in writing and must be hand-delivered or post-marked
within the seven (7) day period and sent by certified mail to Variagenics in
care of Martin Vogelbaum.

Confirmed and Agreed:
                                       Variagenics, Inc.

__________________________________     By: _______________________________
Taylor J. Crouch

Dated: _____________________, 2002     Dated: ______________________, 2002

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       7
<Page>

                                   Schedule A

                               COMPETING BUSINESSES

                                [________________]

                                    [_______]

                                    [_______]

                                [________________]

                                    [_______]

                                    [_______]

                                [________________]

                                    [_______]

                                    [_______]

                                    [_______]

                                    [_______]

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                        8<Page>

                                                                 EXHIBIT 10.26

November 16, 2001

Colin W. Dykes
22 Jarvis Avenue
Hingham, MA 02043

Dear Colin,

         The purpose of this letter agreement (the "Agreement") is to confirm
the terms regarding your separation of employment from Variagenics, Inc.
("Variagenics" or the "Company"). As more fully set forth below, the Company
desires to provide you with certain benefits in exchange for certain
agreements by you.

         1.       SEPARATION OF EMPLOYMENT AND SPECIAL EMPLOYMENT PERIOD.
Your employment with Variagenics will terminate effective upon the expiration
of the Special Employment Period, as defined below (the "Separation Date").
You agree that your separation shall be characterized as a "without cause"
termination. Effective November 19, 2001, you will be relieved of your
existing duties and responsibilities, except those obligations pursuant to
the terms of any confidentiality agreement, inventions agreement and/or
non-competition agreement that you entered into with Variagenics. From the
Effective Date of this Agreement (as defined below) through January 31, 2002,
or such later date as may be mutually agreed in writing, you agree to perform
such duties as the Company may reasonably request from time to time ("Special
Employment Period"). During the Special Employment Period, you may not take
any action on behalf of the Company unless specifically authorized to do so
by the Company. From and after the Separation Date, you shall have no
authority and shall not represent yourself as an employee or agent of the
Company.

         2.       CONSIDERATION. In exchange for the mutual covenants set
forth in this letter, following your execution of this Agreement and the
Company's actual receipt of the signed original of same (the "Effective
Date"), the Company will agree to provide the financial and other
consideration as set forth below:

         (i)      the Company will continue to pay an amount equal to your
         regular salary, less all customary and required taxes and
         employment-related deductions, in accordance with the Company's normal
         payroll practice from November 19, 2001 through the expiration of the
         Special Employment Period ("Special Employment Period Payments");

         (ii)     you will continue to participate in the Company's benefit
         plans, to the extent permissible under the plan documents, during the
         Special Employment Period, including stock option vesting, under
         the same terms and conditions as you currently are participating;

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

<Page>

         (iii)    in the event that you do not continue to work a sufficient
         number of hours during your Special Employment Period to remain on the
         Company's group health insurance plan and such reduction in hours
         constitutes a qualifying event under the Consolidated Omnibus Budget
         Reconciliation Act of 1985 ("COBRA"), you may elect to continue your
         current health and dental insurance benefits pursuant to the terms of
         COBRA. If you elect to continue your health and dental insurance under
         COBRA, the Company will continue to pay its portion of the premium
         during the Special Employment Period. The COBRA qualifying event
         otherwise shall be deemed to occur on the Separation Date. As of the
         Separation Date, you shall be required to pay the full COBRA premium
         rate if you remain on COBRA coverage;

         (iv)     the Company will, effective January 31, 2002, accelerate the
         vesting schedule set forth in the option agreements dated September 30,
         1998, September 22, 1999 and February 11, 2000 between you and the
         Company such that as of January 31, 2002, you will be eligible to
         exercise all of the previously unexercised options granted pursuant to
         such option agreements. Pursuant to the terms of each of the
         above-referenced option agreements, the options must be exercised
         within ninety (90) days after your Separation Date or they will lapse;
         and

         (v)      subject to Section 2(vi) below, at the conclusion of your
         Special Employment Period, the Company will provide you with the
         Supplemental Release, as described in Section 4b of this Agreement.
         Upon the Company's receipt of the signed Supplemental Release, the
         Company shall pay you in the form of salary continuation in accordance
         with our normal payroll practices, the gross amount of one hundred
         twelve thousand five hundred and no/100 (112,500.00) dollars, less all
         applicable federal, state, local withholding and other
         employment-related deductions, which sum represents the equivalent of
         six (6) months of your former annual salary ("Separation Pay").
         Variagenics agrees to continue your participation in the Company's
         health and dental insurance plans during the six month following the
         Separation Date. The Company will also provide you with outplacement
         counseling at no cost to you; however

         (vi)     if you refuse to execute the Supplemental Release at the end
         of the Special Employment Period, you hereby authorize the Company to
         deduct from your Separation Pay up to the full amount of the Special
         Employment Period Payments made to you, less any amounts which you
         earned for actual services rendered by you to the Company during the
         Special Employment Period.

         You acknowledge and agree that the Special Employment Period
Payments and benefits provided under this Section 2 of this Agreement are not
otherwise due or owing to you under any Variagenics employment agreement
(oral or written) or Company policy or practice, and that the foregoing
payments and benefits to be provided to you are not intended to, and shall
not constitute, a severance plan, and shall confer no benefit on anyone other
than the parties hereto. You further acknowledge that, except for the
specific payments and benefits set forth in this Agreement, you are not now
and

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       2
<Page>

shall not in the future be entitled to any other compensation including,
without limitation, other wages, commissions, bonuses (including, equity,
stock, stock options, vacation pay, holiday pay or any other form of
compensation or benefit).

         3.       RETURN OF COMPANY PROPERTY, CONFIDENTIALITY,
NON-COMPETITION, NON-DISPARAGEMENT, BREACH. You expressly acknowledge and
agree to the following:

         (i)      that you have returned to Variagenics all Company documents
         (and any copies thereof) and property (including without limitation all
         keys, badges, credit cards, phone cards, cellular phones, computers,
         etc.); and

         (ii)     that you will abide by the terms of any confidentiality
         agreement and/or inventions agreement that you entered into with
         Variagenics, and that the terms of any such agreements shall survive
         this Agreement. You further acknowledge and agree that you will abide
         by any and all common law and/or statutory obligations relating to
         protection and non-disclosure of Variagenics' trade secrets and/or
         confidential and proprietary documents and information; and

         (iii)    that you reaffirm and continue to be bound by the obligations
                  of Non- Competition/Non-Solicitation as set forth in Section 5
                  of the letter agreement between you and the Company dated July
                  1, 1998 with respect to the following companies, their
                  parents, subsidiaries, divisions, affiliates, successors and
                  related entities: [__________________________________________]
                  Notwithstanding the foregoing, [_____________________________
                  _____________________________________________________________]

         (iv)     that all information relating in any way to this Agreement,
         including the terms and amount of financial consideration provided for
         in this Agreement, shall be held confidential by you and shall not be
         publicized or disclosed to any person (other than an immediate family
         member, legal counsel or financial advisor, provided that any such
         individual to whom disclosure is made agrees to be bound by these
         confidentiality obligations), business entity or government agency
         (except as mandated by state or federal law); and

         (v)      that you will not make any statements that are professionally
         or personally disparaging about, or adverse to, the interests of
         Variagenics (and its officers, directors and employees) including, but
         not limited to, any statements that disparage any such person, product,
         service, finances, financial condition, capability or any other aspect
         of the business of the Company, and that you will not engage in any
         conduct which is intended to harm professionally or personally the
         reputation of Variagenics (and its officers, directors and employees).
         The Company agrees that it will not engage in any conduct that is
         intended to harm your professional or personal reputation; and

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       3
<Page>

         (vi)     that the breach of any of the foregoing covenants by you shall
         constitute a material breach of this Agreement and shall relieve
         Variagenics of any further obligations hereunder and, in addition to
         any other legal or equitable remedy available to the Company, shall
         entitle the Company to recover any consideration already paid to you
         pursuant to Section 2 of this letter. Any breach of this Agreement by
         you and/or the repayment of any sums pursuant to this provision shall
         not relieve you of your obligations under this Agreement, which shall
         remain in full force and effect.

         4a.      RELEASE OF CLAIMS. You hereby agree and acknowledge that by
         signing this Agreement you are waiving your right to assert any form of
         legal claim against Variagenics(1) whatsoever for any alleged action,
         inaction or circumstance existing or arising from the beginning of time
         through the date on which you sign this Agreement. To the extent
         permitted by law, your waiver and release herein is intended to bar any
         form of legal claim, charge, complaint or any other form of action
         (jointly referred to as "Claims") against Variagenics seeking any form
         of relief including, without limitation, equitable relief (whether
         declaratory, injunctive or otherwise), the recovery of any damages or
         any other form of monetary recovery whatsoever (including, without
         limitation, back pay, front pay, compensatory damages, emotional
         distress damages, punitive damages, attorneys fees and any other costs)
         against Variagenics, for any alleged action, inaction or circumstance
         existing or arising through the date on which you sign this Agreement.

         Without limiting the foregoing general waiver and release, you
specifically waive and release Variagenics from any Claims arising from or
related to your employment relationship with the Company or the termination
thereof, including without limitation:

         (i)      Claims under any local, state, federal or foreign
                  discrimination, fair employment practices or other employment
                  related statute, regulation or executive order (as they may
                  have been amended through the date on which you sign this
                  Agreement) prohibiting discrimination or harassment based upon
                  any protected status including, without limitation, race,
                  religion, citizenship, national origin, age, gender, genetic
                  carrier status, marital status, disability, veteran status or
                  sexual orientation. Without limitation, specifically included
                  in this paragraph are any Claims arising under the federal Age
                  Discrimination in Employment Act, the Older Workers Benefit
                  Protection Act, the Civil Rights Acts of 1866 and 1871, Title
                  VII of the Civil Rights Act of 1964, the Civil Rights Act of
                  1991, the Equal Pay Act, the Immigration Reform and Control
                  Act, the Americans With Disabilities Act and any similar
                  local, state, federal or foreign statute or law.

-------------------------

(1)      For the purposes of this Section, the parties agree that the term
"Variagenics" shall include Variagenies, Inc., its divisions, affiliates,
parents and subsidiaries, and its and their respective officers, directors,
employees, agents and assigns.

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       4
<Page>

         (ii)     Claims under any other local, state, federal or foreign
                  employment related statute, regulation or executive order (as
                  they may have been amended through the date on which you sign
                  this Agreement) relating to wages, hours or any other terms
                  and conditions of employment. Without limitation, specifically
                  included in this paragraph are any Claims arising under the
                  Fair Labor Standards Act, the Family and Medical Leave Act of
                  1993, the National Labor Relations Act, the Employee
                  Retirement Income Security Act of 1974, the Consolidated
                  Omnibus Budget Reconciliation Act of 1985 (COBRA) and any
                  similar local, state, federal or foreign statute or law.

         (iii)    Claims under any local, state, federal or foreign common law
                  theory including, without limitation, wrongful discharge,
                  breach of express or implied contract, promissory estoppel,
                  unjust enrichment, breach of a covenant of good faith and fair
                  dealing, violation of public policy, defamation, interference
                  with contractual relations, intentional or negligent
                  infliction of emotional distress, invasion of privacy,
                  misrepresentation, deceit, fraud or negligence.

         (iv)     Any other Claim arising under local, state, federal or
                  foreign law.

         YOU EXPLICITLY ACKNOWLEDGE THAT BECAUSE YOU ARE OVER FORTY (40)
YEARS OF AGE, YOU HAVE SPECIFIC RIGHTS UNDER THE AGE DISCRIMINATION IN
EMPLOYMENT ACT ("ADEA") AS AMENDED AND THE OLDER WORKERS BENEFITS PROTECTION
ACT ("OWBPA"), WHICH PROHIBIT DISCRIMINATION ON THE BASIS OF AGE, AND THAT
THE RELEASES SET FORTH IN THIS SECTION ARE INTENDED TO RELEASE ANY RIGHT THAT
YOU MAY HAVE TO RECOVER DAMAGES FROM VARIAGENICS ALLEGING DISCRIMINATION ON
THE BASIS OF AGE.

         IT IS VARIAGENICS' DESIRE AND INTENT TO MAKE CERTAIN THAT YOU FULLY
UNDERSTAND THE PROVISIONS AND EFFECTS OF THIS AGREEMENT. TO THAT END, YOU
HAVE BEEN ENCOURAGED AND GIVEN THE OPPORTUNITY TO CONSULT WITH LEGAL COUNSEL
FOR THE PURPOSE OF REVIEWING THE TERMS OF THIS AGREEMENT. CONSISTENT WITH THE
PROVISIONS OF THE OWBPA, VARIAGENICS IS PROVIDING YOU WITH TWENTY-ONE (21)
DAYS IN WHICH TO CONSIDER AND ACCEPT THE TERMS OF THIS AGREEMENT BY SIGNING
BELOW AND RETURNING IT TO MARY A. MCWEENEY, 60 HAMPSHIRE STREET, CAMBRIDGE,
MA 02139. IN ADDITION, YOU MAY RESCIND YOUR ASSENT TO THIS AGREEMENT WITHIN
SEVEN (7) DAYS AFTER YOU SIGN IT. TO DO SO, YOU MUST DELIVER A NOTICE OF
RESCISSION TO MARY A. MCWEENEY. TO BE EFFECTIVE, SUCH RESCISSION MUST BE HAND
DELIVERED OR POSTMARKED WITHIN THE SEVEN (7) DAY PERIOD AND SENT BY CERTIFIED
MAIL, RETURN RECEIPT REQUESTED, TO MARY A. MCWEENEY, 60 HAMPSHIRE STREET,
CAMBRIDGE, MA 02139.

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       5
<Page>

         Notwithstanding the foregoing, this section does not release
Variagenics from any obligation expressly set forth in this Agreement nor
does it release any claims that by law cannot be released or waived.

         You acknowledge and agree that but for providing this waiver and
release, you would not be receiving the Special Employment Payments or other
consideration provided to you under this Agreement.

         4b.      SUPPLEMENTAL RELEASE. Following your Separation Date, in
exchange for the consideration provided in Section 2 of this Agreement, you
agree to execute the Supplemental Release attached hereto as EXHIBIT A.

         5.       ENTIRE AGREEMENT/CHOICE OF LAW/ENFORCEABILITY. You
acknowledge and agree that, with the exception of (i) any confidentiality and
inventions agreements signed by you; (ii) any non-competition agreements
signed by you; and (iii) any stock option grant letter and any stock option
plan referenced therein, the terms of which are hereby incorporated by
reference and shall survive this Agreement, this Agreement supersedes any and
all prior or contemporaneous oral and/or written agreements between you and
Variagenics, and sets forth the entire agreement between you and Variagenics.
No variations or modifications hereof shall be deemed valid unless reduced to
writing and signed by the parties hereto. This Agreement shall be deemed to
have been made in the Commonwealth of Massachusetts, shall take effect as an
instrument under seal within Massachusetts, and shall be governed by and
construed in accordance with the laws of Massachusetts, without giving effect
to conflict of law principles. You agree that any action, demand, claim or
counterclaim relating to the terms and provisions of this Agreement, or to
its breach, shall be commenced in Massachusetts in a court of competent
jurisdiction, and you further acknowledge that venue for such actions shall
lie exclusively in Massachusetts and that material witnesses and documents
would be located in Massachusetts. The provisions of this letter are
severable, and if for any reason any part hereof shall be found to be
unenforceable, the remaining provisions shall be enforced in full.

         By executing this Agreement, you are acknowledging that you have
been afforded sufficient time to understand the terms and effects of this
letter, that your agreements and obligations hereunder are made voluntarily,
knowingly and without duress, and that neither Variagenics nor its agents or
representatives have made any representations inconsistent with the
provisions of this letter.

         If the foregoing correctly sets forth our understanding, please
sign, date and return the enclosed copy of this letter to Mary A. McWeeney,
Senior Director of Human Resources at Variagenics within 21 days. This
agreement may be executed in counterpart.

Very truly yours,

VARIAGENICS, INC.

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       6
<Page>

By:  /s/  Taylor J. Crouch
   -------------------------------
   Taylor J. Crouch
   President & CEO

Dated:    12/04/01
      ----------------------------

CONFIRMED AND AGREED:

 /s/ Colin W. Dykes
----------------------------------
Colin W. Dykes

Dated:   12/05/01
      ----------------------------

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       7
<Page>

                                    EXHIBIT A

                              SUPPLEMENTAL RELEASE

         You hereby agree and acknowledge that by signing this Supplemental
Release, you are waiving your right to assert any form of legal claim against
Variagenics(2) whatsoever for any alleged action, inaction or circumstance
existing or arising from the beginning of time through the date on which you
sign this Supplemental Release. To the extent permitted by law, your waiver
and release herein is intended to bar any form of legal claim, charge,
complaint or any other form of action (jointly referred to as "Claims")
against Variagenics seeking any form of relief including, without limitation,
equitable relief (whether declaratory, injunctive or otherwise), the recovery
of any damages or any other form of monetary recovery whatsoever (including,
without limitation, back pay, front pay, compensatory damages, emotional
distress damages, punitive damages, attorneys fees and any other costs)
against Variagenics, for any alleged action, inaction or circumstance
existing or arising through the date on which you sign this Supplemental
Release.

         Without limiting the foregoing general waiver and release, you
specifically waive and release Variagenics from any Claims arising from or
related to your employment relationship with the Company or the termination
thereof, including without limitation:

         (i)      Claims under any local, state, federal or foreign
                  discrimination, fair employment practices or other employment
                  related statute, regulation or executive order (as they may
                  have been amended through the date on which you sign this
                  Supplemental Release) prohibiting discrimination or harassment
                  based upon any protected status including, without limitation,
                  race, religion, citizenship, national origin, age, gender,
                  genetic carrier status, marital status, disability, veteran
                  status or sexual orientation. Without limitation, specifically
                  included in this paragraph are any Claims arising under the
                  federal Age Discrimination in Employment Act, the Older
                  Workers Benefit Protection Act, the Civil Rights Acts of 1866
                  and 1871, Title VII of the Civil Rights Act of 1964, the Civil
                  Rights Act of 1991, the Equal Pay Act, the Immigration Reform
                  and Control Act, the Americans With Disabilities Act and any
                  similar local, state, federal or foreign statute or law.

         (ii)     Claims under any other local, state, federal or foreign
                  employment related statute, regulation or executive order (as
                  they may have been amended through the date on which you sign
                  this Supplemental Release) relating to wages, hours or any
                  other terms and conditions of employment. Without

--------------------
(2)     For purposes of this Section the parties agree that the term
"Variagencixs" shall include Variagenics, Inc., its divisions, affiliates,
parents and subsidiaries, and its and their respective officers, directors,
employees, agents and assigns.

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       8
<Page>
                  limitation, specifically included in this paragraph are any
                  Claims arising under the Fair Labor Standards Act, the Family
                  and Medical Leave Act of 1993, the National Labor Relations
                  Act, the Employee Retirement Income Security Act of 1974, the
                  Consolidated Omnibus Budget Reconciliation Act of 1985 (COBRA)
                  and any similar local, state, federal or foreign statute or
                  law.

         (iii)    Claims under any local, state, federal or foreign common law
                  theory including, without limitation, wrongful discharge,
                  breach of express or implied contract, promissory estoppel,
                  unjust enrichment, breach of a covenant of good faith and fair
                  dealing, violation of public policy, defamation, interference
                  with contractual relations, intentional or negligent
                  infliction of emotional distress, invasion of privacy,
                  misrepresentation, deceit, fraud or negligence.

         (v)      Any other Claim arising under local, state, federal or
                  foreign law.

         YOU EXPLICITLY ACKNOWLEDGE THAT BECAUSE YOU ARE OVER FORTY (40) YEARS
OF AGE, YOU HAVE SPECIFIC RIGHTS UNDER THE AGE DISCRIMINATION IN EMPLOYMENT ACT
("ADEA") AS AMENDED AND THE OLDER WORKERS BENEFITS PROTECTION ACT ("OWBPA"),
WHICH PROHIBIT DISCRIMINATION ON THE BASIS OF AGE, AND THAT THE RELEASES SET
FORTH IN THIS SECTION ARE INTENDED TO RELEASE ANY RIGHT THAT YOU MAY HAVE TO
RECOVER DAMAGES FROM VARIAGENICS ALLEGING DISCRIMINATION ON THE BASIS OF AGE.

         IT IS VARIAGENICS' DESIRE AND INTENT TO MAKE CERTAIN THAT YOU FULLY
UNDERSTAND THE PROVISIONS AND EFFECTS OF THIS AGREEMENT. TO THAT END, YOU
HAVE BEEN ENCOURAGED AND GIVEN THE OPPORTUNITY TO CONSULT WITH LEGAL COUNSEL
FOR THE PURPOSE OF REVIEWING THE TERMS OF THIS AGREEMENT. CONSISTENT WITH THE
PROVISIONS OF THE OWBPA, VARIAGENICS IS PROVIDING YOU WITH TWENTY-ONE (21)
DAYS IN WHICH TO CONSIDER AND ACCEPT THE TERMS OF THIS AGREEMENT BY SIGNING
BELOW AND RETURNING IT TO MARY A. MCWEENEY, 60 HAMPSHIRE STREET, CAMBRIDGE,
MA 02139. IN ADDITION, YOU MAY RESCIND YOUR ASSENT TO THIS AGREEMENT WITHIN
SEVEN (7) DAYS AFTER YOU SIGN IT. TO DO SO, YOU MUST DELIVER A NOTICE OF
RESCISSION TO MARY A. MCWEENEY. TO BE EFFECTIVE, SUCH RESCISSION MUST BE HAND
DELIVERED OR POSTMARKED WITHIN THE SEVEN (7) DAY PERIOD AND SENT BY CERTIFIED
MAIL, RETURN RECEIPT REQUESTED, TO MARY A. MCWEENEY, 60 HAMPSHIRE STREET,
CAMBRIDGE, MA 02139.

         Notwithstanding the foregoing, this section does not release
Variagenics from any obligation expressly set forth in this Agreement nor
does it release any claims that by law cannot be released or waived.

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       9
<Page>

         You acknowledge and agree that but for providing this waiver and
release, you would not be receiving the Special Employment Payments and other
consideration provided to you by the Company.

CONFIRMED AND AGREED:                  VARIAGENICS, INC.

/s/ Colin W. Dykes                     By:  /s/ Taylor J. Crouch
----------------------------------        --------------------------------
Colin W. Dykes                            Taylor J. Crouch
                                          President & CEO

Dated: December 5, 2001                Dated: December 4, 2001

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       10
<Page>

January 25, 2002

Colin W. Dykes
22 Jarvis Avenue
Hingham, MA 02043

Dear Colin,

Pursuant to the terms of Paragraph 1 in the Letter Agreement between
Variagenics, Inc. and you dated November 16, 2001, we propose to extend the
Special Employment Period as set forth in the Letter Agreement from January
31, 2002 to March 1, 2002.

If you are in agreement with this extension, please acknowledge by signing
below.

Sincerely yours,

/s/ Taylor J. Crouch
--------------------

Taylor J. Crouch
President & CEO

                                       AGREED:

                                       /s/ Colin W. Dykes
                                       -----------------------------------
                                           Colin W. Dykes

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}]]